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Abstract
Botulinum toxin (BT) is an injectable intermuscular medication that is used as a muscle 
relaxant. In this chapter, we explore the applications of botulinum toxin in dentistry for 
either cosmetic or therapeutic purpose, such as gummy smile (high lip line), parafunctional 
habits, temporomandibular disorders and facial pain. It is considered as a non-invasive, 
conservative and affordable alternative treatment in comparison to surgical procedures. 
Although, the effect of BT is temporary that lasts for 4–6 months, it is preferred by most 
of the patients as it gives positive significant results that meet their desires with minimal 
side effects.
Keywords: Botox, botulinum toxin, gummy smile, temporomandibular joint disorder, 
asymmetric smile, reverse smile, drooping mouth corners, facial nerve palsy, migraine, 
excessive salivation, trigeminal neuralgia, parafunctional habits, maxillofacial fracture
1. Introduction
Botulism toxins are exotoxins produced by anaerobic, Gram-positive, rod-shaped, motile 
bacteria of the genus Clostridium, which is called Clostridium botulinum, C. butyricum, C. 
baratii and C. argentinense [1], which are widely distributed in the surrounding environ-
ment, including the soil and dust. Also, some food products such as honey, canned and 
not well cooked food may contain amounts of these bacteria [2]. These bacteria are divided 
into four distinct phenotypic groups (I–IV) and is also classified into seven serotypes (A–G) 
based on the antigenicity of the botulinum toxin produced [3]. The most common ones are 
Botulinum toxin type A and B. However, Onabotulinumtoxin A is marketed under brand 
names Botox®, Vistabel® and Vistabex®, while Abobotulinumtoxin A is marketed under 
the brand names Dysport® and Azzalure®. In addition, incobotulinumtoxin A is marketed 
under the brand names Xeomin®, Xeomeen®, and Bocouture®. Whereas, botulinum toxin 
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B has approval under the brand name Myobloc® and Neurobloc®. All of them are inject-
able intramuscular medications that are used as muscle relaxants. In 2007, British Columbia 
dentists were among the first to use botulinum toxin (BT) for cosmetic treatments, and to 
subsequently appreciate the potential in dental therapeutic treatments [4]. Now, A growing 
number of dentists are practicing botulinum toxin (BT) injections for their patients for oral 
and maxillofacial cosmetic and therapeutic uses.
2. Mechanism of action
When BT is injected into a target muscle, it creates a temporary dose-dependent effect that 
weakens muscles activity. It is a neurotoxin which produces transient chemical denervation of 
facial muscle by binding to glycoproteins structures and inhibiting the release of acetylcholine 
from the cholinergic nerve endplates, which leads to decrease in the contraction intensity, 
flaccid paralysis and muscle inactivity. When the target tissue is an exocrine gland, the glan-
dular secretion is blocked as it inactivates the glands innervated. However, the neuromus-
cular transmission is re-established by restoration of the SNARE protein complex turnover, 
initiation of new acetylcholine receptors, sprouting of new axonal terminals and elongation of 
the endplate. The effect can usually last up to 3 months and gradually returns to its full func-
tion with no adverse effects. Therefore, the blockage is transient and not permanent which 
make this treatment considered as a palliative approach rather than a curative option [5].
3. Preparations
BT is shipped frozen and it is recommended to be kept in at frozen temperature −5°C before 
use as lower temperature may affect its potency. Doses of BT utilized for the treatment of 
a particular purpose depend on the certain brand/preparation as the unit of one product is 
not similar to the other [6]. The two most commercially available types of BT are Botox® and 
Dysport®. About 20–25 units of Botox® are equipotent to 80 units of Dysport®. Botox® is mar-
keted as single-use, sterile 100 Units or 200 Units vacuum-dried powder while the vial of 
Dysport® contains 500 units. They are reconstituted only with sterile, non-preserved 0.9% 
sodium chloride (normal saline solution) [7]. However, there is no established method to 
calculate the equivalent doses between various products of BT. The potency per unit of a 
product is not interchangeable with other preparations, therefore it is important for a dentist 
to be aware of the different formulations before their use [8].
After drawing up of preservative-free saline by an appropriate sized needle and syringe, it is 
important to introduce the saline slowly into the vial, then mix by gentle rotating movement to 
avoid foaming and denaturation of the toxin. After that, storing of BT in a frozen vial (2–4°C) 
is recommended [9]. However, it has been reported that higher dilutions of BT can lead to an 
increase of its tissue diffusion, thus influencing the therapeutic and side effects. So far, no valid 
studies are available to evaluate the optimal dilution for different therapeutic situations [5]. 
The BT potency has been reported to be effective until the fourth week after reconstitution [10].
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4. Injection procedures
The preferred syringe for BT injections is a calibrated 1.0 mL tuberculin syringe with a gauge 
preference of 26–30 [11]. The patient should be placed in upright raised position, the target 
facial muscle should be examined by inspection and palpation when the patient is making 
the facial expressions or just clenching to determine the exact area of the injections. The 
injectable areas should be sterilized with a non-alcohol cleanser such as Betadine. Topical 
anesthesia and ice could be applied before injection to control pain and bleeding the Botox 
is then injected into the desired areas. It is recommended to apply pressure to the injected 
area if there is bleeding. After finishing the procedure, the patient should lay upright for 
2–5 min to assure his wellness and receive the postoperative instructions which are; avoid-
ing lying down for 4 h, avoid strenuous activity for at least 24 h to avoid the risk of bruising, 
non-steroidal anti-inflammatory drugs will be prescribed if patients complained of pain or 
headache, ice packs are advisable after injection to reduce bleeding and edema. However, as 
the injection of BT is intramuscular, the dosage of BT injection varies between females and 
males, depending on the volume of muscle. Certainly, males have a larger muscle volume 
than females, so they require more units of BT during injection to achieve the same results 
as female patients [12].
Results will be conspicuous within 4–14 days and lasts for 4–6 months, depending on the 
muscle thickness and anatomy. Some authors [13, 14] conducted that several injections of 
BT could prolong its effect. One explanation of this process is that the extended muscle 
paralysis that occurs after numerous injections can cause partial muscle atrophy and per-
manent weakness in the contraction ability later on, even after the evanescence of the BT 
toxic effect [15]. It is important to avoid BT injections before the complete disappearance of 
the BT effect to prevent the antibodies formation against the toxins, which can lately lead to 
 disappointing results [16].
5. Contraindications
1. Pregnant or lactating woman as it may harm the baby (Botox is classified as pregnancy 
category C drugs) [7].
2. Neuromuscular disorders as patients will be at risk of muscle weakness, diplopia, ptosis, 
dysphonia, dysarthria and severe dysphagia [7].
3. Patients under Ca channel blockers, cyclosporine and aminoglycosides medications as it 
may cause arrhythmia and myocardial infarction [7].
4. Patients with a history of allergy to any of the constituents of BT or saline solution as 
it may cause immediate hypersensitive reactions including anaphylaxis, serum sickness, 
urticaria, edema and dyspnea [7].
5. Psychological unstable patients [7].
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6. Side effects and complications
Generally, the Botox treatment is safe when it is administered in proper doses and techniques. 
The complications of BT are divided into systemic, local, and reduced therapeutic effects due 
to antibody formation. The systemic complications include nausea, loss of appetite, diarrhea, 
abdominal pain, fatigue, malaise, flu-like symptoms such as fever and running nose, increased 
blood pressure, sore throat, modification of salivary consistency, difficulty in swallowing and 
ringing in ears [17]. While local complications vary regarding the injection site, involving 
infection, headache, pain at the injection site, bruising, inflammation, orofacial edema, loss of 
muscle strength, nerve palsy, rash, itching, ptosis, dry eye syndrome and dysphonia. In addi-
tion, improper injection technique or dose may result in asymmetrical appearance of a face 
or smile, some difficulties in speech, chewing and/or drinking, alternation in salivary consis-
tency and drooping or ptosis of the lip causing obstruction of visible teeth on full smile [16].
In some cases, BT action may diffuse to sites beyond the local application site, presenting 
generalized muscle weakness manifesting as diplopia, dysphagia, dysphonia, ptosis or even 
breathing difficulties. The probability of this spread of toxin effect is considered to be high in 
the face as well as head and neck region due to facial planes and spaces.
The lethal dose of BT injections is not known yet, but it has been estimated to be about 3000 U 
[18]. The maximum dose recommended for dental applications at an injection session is about 
80–100 U. Therefore, more doses could have a potentially lethal outcome.
7. Uses and indications of Botox in dentistry
Certainly, BT treatments have been amplified in popularity over the last two decades, it is get-
ting much more attention in dentistry and frustrated many dentists, where they use BT injections 
for dental esthetic and therapeutic purposes. It was proven that BT injections can improve cos-
metics, reduce pain and relax retrain muscles which in turn enhance the dental treatment plans.
The applications of BT injections have been classified into:
I. Cosmetic uses
1. Gummy smile
2. Asymmetric smile
3. Sad/reverse smile (Marionette lines)
4. Perioral rhytides (Smoker lines)
5. Masseteric hypertrophy (bulky jaws)
II. Therapeutic uses
1. Tempomandibular joint disorder
2. Migraine
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3. Trigeminal neuralgia
4. Facial nerve palsy
5. Bruxism and parafunctional habits
6. Salivary gland secretory disorders (excessive salivation/drooling)
7. Maxillofacial trauma and fractures
8. As adjunctive treatments in dental clinics
7.1. Cosmetic uses
7.1.1. Gummy smile
Although, displaying a small amount of gingiva is esthetically acceptable and gives a youth-
ful appearance, a smile with more than 2 mm exposed gingiva is known to be gummy smile 
(GS). It is one of the most common variations among the people, with predominance of 
females than males. The etiological factors of GS can extensively vary, including altered pas-
sive eruption of teeth, dentoalveolar extrusion, vertical maxillary excess, short or hyperactive 
upper lip muscles (levator labii superioris, levator labii superioris alaeque nasii, levator anguli 
oris, depressor septi and the zygomaticus muscles), or combinations of one or more of them 
(Figure 1). Accordingly, proper diagnosis of the etiology will lead to the proper treatment 
[16]. In case of altered passive eruption, crown lengthening is the choice treatment, whether 
with or without bone reduction. Also, surgical lip repositioning techniques were reported to 
give satisfactory results. In addition, some cases need orthognathic surgery or orthodontic 
appliances, especially if the cause is skeletal in origin.
However, in cases of hyperactive/hyper-functional elevator labial muscles, BT injections have 
progressed to be popular in the correction of the gummy smile (GS) compared to other surgical 
procedures. The advantages of these injections are the increase of the patient self-esteem and 
Figure 1. Facial muscles and the direction of their action (depression or elevation).
Botulinum Toxin in Dentistry
http://dx.doi.org/10.5772/intechopen.78950
87
their preference because their technique is less invasive, reasonable cost and requires less time 
despite its short-term effect. The purpose of the BT injections is to relax the hyperactive eleva-
tor muscles, blocking excessive contractions that are excessively pull up the lip while smiling.
Injection technique: during smile, there are 2 stages in its development, the first stage hap-
pens when the upper lip raises to the nasolabial fold, the medial muscle bundles pull up the 
lip at the anterior teeth and the lateral muscle groups raise the lips at the posterior teeth. 
However, buccal fats resist the lips at the nasolabial fold while during the second stage, the lip 
raise superiorly by three muscle groups which are levator labii superioris, zygomaticus major 
and superior fibers of buccinators [19]. First, gummy smile should be diagnosed according to 
the classification of the exposed gingival area; anterior, posterior, mixed and asymmetrical 
or by Goldstein classification as low, moderate and high based on the amount of exposure 
of gingiva during smiling. These classifications are essential to identify the involved muscle, 
dose and technique of Botox injections. The muscles of injection are levator Labii superioris, 
superioris alaeque nasi, zygomaticus minor and major muscle, depressor septi nasi muscle 
and risorius muscle. The sites of injection should be determined first by palpating the muscles 
during smiling and relaxing movements to ensure the accurate locations of injections. There 
is an appropriate and effective point of intramuscular Botox injection introduced by Hwang 
et al., at Yonsei University College of dentistry, Seoul, Korea have where elevator lip muscles 
pass by, it is called Yonsei point as shown in Figure 2 [20]. This point is located at the center 
of the triangle formed by levator labii superioris, levator labii superioris alaeque nasi and 
Figure 2. Sites of botox injections for the cosmetic uses.
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zygomaticus minor. The doses depend on the dilution of BT with saline. However, there are 
different techniques for gummy smile injections, all of them have a common site of injection 
which is Yonsei point, where the recommended dose is 3 U at each injection site. The depth 
of administration should be intramuscular with the needle perpendicular to the skin surface 
and bevel facing upwards [16].
7.1.2. Asymmetric smile
Asymmetrical smiles (AS) are due to unilateral hyperkinetic of either lip elevator muscles or 
lip depressor muscles, where lip rises or depressed more on one side than the other due to the 
imbalance of the muscle intensity or activity between the left and right sides during smiling. 
Lip elevator muscles are the muscles responsible for upper AS while the depressor labii infe-
rioris and depressor anguli oris are the muscles responsible for lower AS. However, injections 
of BT into the muscles of the side where the upper lip pulled to the highest side or the lower 
lip retracted to the lower side, shown to be effective and give positive results [20, 21].
Injection technique: for upper AS, patient should be in the right position and asked to smile, 
2–3 U at the Yonsei point should be injected unilaterally to the most elevated side. While 
for the lower AS, patient should be asked to smile to determine which side has pulled lip 
down then, 2–3 U of Botox injections into one of depressor labii inferioris muscles as shown 
in Figure 2 and 2 U in one of depressor anguli oris. For both techniques, the needle should 
passed perpendicular to the skin and enter the thickest part of the muscle. It is advisable to 
give small doses to correct AS, otherwise, excessive weakening and over correction may result.
7.1.3. Sad or reverse smile (Marionette lines)
The presence of the cervical commissures of the lips in combination with the rest of facial 
anatomical features are responsible for the old or sad appearance. This happens due to age 
changes as skin loses the consistency of collagen and elastic fibers and also due to the hyper-
active of depressor anguli oris (triangularis muscle) that is located bilaterally (Figure 1), adja-
cent to the lip corners which causes the drooping mouth corners and gives the Marionette 
line appearance. However, BT injections has proved its effectiveness and give satisfactory 
outcomes in such cases, it relaxes the depressor muscles which in turn lift the lip corners pre-
cisely through their antagonists, improving the depressed and aged facial appearance [22, 23].
Injection technique: Botox injections are indicated for patients with horizontal and verti-
cal platysma muscle bands and with downturned oral commissures, without the existence 
of submental lipodystrophy or excessive skin laxity [22]. Before injection, patient should be 
asked to frown, then muscles should be palpated to detect the exact sites of injection. Also, 
muscle can be detected by bimanual palpation at angle of mouth when the patient says “iii”. 
The site of injection is on the trajectory of nasolabial fold to the jaw line. Bilateral superficial 
injections in doses of about 2–5 U of Botox is the norm (Figure 2). However, it is difficult to 
inject the depressor anguli oris muscle because its medial border overlaps with the depressor 
labii inferioris, and its lateral border is adjacent to the risorius, zygomaticus major, and pla-
tysma muscles. Therefore, precautions should be taken as if Botox is injected with improper 
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dose, possible negative outcomes may result including drooling, slurred speech and lack of 
facial expressions [22]. In addition, if it is injected medially, Botox may diffuse into the depres-
sor labii inferiors causing a lower lip protrusion appearance, known as a Gomer Pyle look and 
if it is injected too laterally, it may reach Buccinator muscle, causing the patient to bite and 
traumatize the buccal mucosa.
7.1.4. Perioral rhytides (smoker lines)
These are vertical rhytides which are present in the upper lip and the lower lip region. It 
is caused by hypertrophic or repetitive contractions of orbicularis oris (circles the mouth) 
increased with age, sun exposure, strawing and smoking. Their treatment choices are Botox 
injections or dermal filler or both of them together. Although, BT injections will treat the verti-
cal wrinkles around the lips, they give more eversion results and more lip fullness appearance 
which make them, the first choice [24].
Injection technique: ask the patient to close his lips and push them forwards, injections should 
be very superficial of 1–2 U at 2–4 spaced sites along the vermilion border to assure symmetry 
(Figure 2). Results do not last too long because of the repeated action of same muscles, but 
after injection patient may complain of difficulty in swishing, spitting, strawing, whistling, 
kissing and pronouncing. In addition, asymmetry may result during taking and smiling [24].
7.1.5. Masseteric hypertrophy (bulky jaws)
Masseteric hypertrophy is an asymptomatic unilateral or bilateral enlargement of the mas-
seter muscles due to congenital cause, chronic clenching habits, asymmetric chewing habit, 
TMJ dysfunction and focal dystonia. Thus, causing the bulk of mandibular jaw and square 
appearance of the face. The traditional treatment is partial resection surgery of masseter 
muscle under general anesthesia, which make this choice have several complications, includ-
ing hematoma, nerve paralysis, infection, mouth opening restriction and sequel from general 
anesthesia [25]. Botox injections of masseter muscle reported to be safe as it causes weakening 
in its intensity and reduction of its bulking appearance which in turn give more tapered face 
and jaw line contouring [26].
Injection technique: the patient should be asked to clench his teeth to determine the most 
bulky and prominent area in the masseter muscle for Botox injections, the injections are 
equally given into three points at the center of the lower third of the masseter muscle with 
a distance 1 cm from each other, 5–15 U in each point total of 15–45 U per side (Figure 3) 
depending on the bulk of the muscle [26].
7.2. Therapeutic uses
7.2.1. Tempomandibular joint disorder
TMJ disorder is a term used to describe orthopedic and myofascial disorders that cause 
disharmony in the temporomandibular joint (TMJ), masticatory muscles, and associated 
structures. It is associated with oromandibular dystonia, periauricular pain, cervicogenic 
headaches, chronic low back pain, decreased jaw excursion, jaw locking, and noise at the 
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joint with movement. The etiological factors include excessive masticatory muscle activity, 
parafunctional habits, trauma, psychological factors, and diseases such as arthritis [27]. In 
general, TMJ disorders are divided into myofacial TMJ disorder or arthrogenic TMJ disor-
der. The myofacial TMJ disorder is manifested by a pain from hyperfunctioning masticatory 
muscles causing chronic myositis. While, arthrogenic TMJ disorder is associated with pain 
due to intracapsular pathology [28].
The diagnosis of TMJ disorders is based on history, physical findings and clinical examina-
tion. Patient should be asked about bruxism, gum chewing, jaw soreness, morning headaches 
and history of trauma [26]. However, there are several therapeutic modalities for TMJ dis-
orders, which are occlusal equilibrations, full mouth reconstructions, orthotic devices, jaw 
repositioning, psychological therapy, neuromuscular therapy, physiotherapy and laser. In 
addition, systemic pharmacological medications can play a role in its management, such as 
corticosteroids injections, anti-inflammatory agents, non-narcotic and narcotic pain medica-
tions, muscle relaxants and in some cases tricyclic antidepressants [29, 30]. However, some 
patients with arthrogenic TMJ disorder may be treated by intra-articular corticosteroid injec-
tions, arthrocentesis, arthroscopic surgery or TMJ open surgeries such as arthroplasty [28].
Some dental practitioners solve the occlusion problem and achieve ideal occlusion without 
treating the spasm of the masticatory muscles. Thus, will lead to the recurrence of sign and 
symptoms of TMJ disorders and failure of the treatment. Hereby, muscle spasm should be 
relieved first to reduce facial pain, then achieve the proper occlusal equilibration. However, 
the use of Botox is considered to be an effective supportive treatment of the myofacial TMJ 
disorder, especially with patients who did not achieve complete remission by conserva-
tive and pharmacological modalities. It decreases the intensity, frequency and duration of 
recurrent attacks [28].
Figure 3. Injection points of Masseteric hypertrophy (5–15 U for each point).
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Injection technique: the involved muscles are temporalis muscle and masseter muscle which 
are manifested as direct muscle pain while lateral pterygoid muscle involvement usually is 
manifested as buccal pain [31]. To identify the injected sites, first ask the patient to clench 
his teeth to make the injection muscles more prominent and easily detected. Injections are 
performed bilaterally using the proper dose of BT to reduce the contractions of these muscles 
as well as the facial pain. Identification of the lateral pterygoid muscle is done intraorally 
where needle placed between the pterygoid plate and the coronoid process of the mandible. 
The starting dose of Botox 10–25 U for a temporalis muscle, 25–50 U to a masseter muscle 
(Figure 4) and 7.5–10 U for the lateral pterygoid [28]. It is recommended to give low concen-
trations in different sites to increase the areas of injections and avoid incomplete effect. Higher 
doses may increase the risk of diffusion of Botox to undesired neighboring areas causing 
brow ptosis, blepharoptosis or diplopia if the temporalis muscle is injected too close to the 
orbit and if the masseter muscle is injected too close to the zygomaticus major, asymmetry 
may result. Also, dry mouth may occur if BT is injected into the parotid gland [32].
7.2.2. Migraine
The migraine headache is a common neurological condition that is characterized by unilat-
eral pulsatile throbbing pain, photophobia, phonophobia, feeling of nausea or vomiting and 
disabling intensity, its effect lasts from 4 to 72 h and may be longer [33]. It was reported that 
migraine has a relation to family history and its incidence in women is three times that in men 
with the highest prevalence among those aged 30–39 [34]. Treatment of migraine includes 
abortive and preventive therapy. The treatments for mild to moderate episodes are nonste-
roidal anti-inflammatory drugs (NSAD) and analgesics containing acetaminophen or aspirin. 
While, for severe migraine, Triptans are indicated. Not only, some patients with migraine 
respond poorly to triptans, but also it is contraindicated in some cases such as cardiovas-
cular co-morbidities [35, 36]. Intravenous administration of some combination of dopamine 
receptor agonists (e.g., prochlorperazine), dihydroergotamine (DHE), and intravenous (IV) 
NSAIDs (diclofenac or ketorolac) is recommended for more severe attacks [37].
In 2000, Binder found that individuals who had cosmetic facial injections reported a pain 
reduction of the headache [38]. After that, they discovered that the relief of the pain often 
happened before the decrease in muscle contractions [39]. Botox blocks the release of periph-
eral nociceptive neurotransmitters, modulating the peripheral sensation and also suppresses 
indirectly the central pain processing systems responsible for migraine [40]. In 2010, the FDA 
approved intramuscular BT injections as a prophylactic treatment of migraine [41].
Injection technique: muscles to be injected by BT are procerus, corrugator, frontalis, tem-
poralis, occipitalis and posterior cervical muscles. The FDA has approved 31 sites with total 
165–195 U at which BT can be injected for treating migraines. The injections are given to 
corrugator in 10 U divided into 2 sites, procerus 5 U is given in one site, frontalis 20 U divided 
into 4 sites, temporalis 40 U divided into 8 sites (Figures 4 and 5), occipitalis 30 U divided 
into 6 sites, cervical paraspinal muscles 20 units divided into 4 sites and finally trapezius 30 U 
divided into 6 sites [42]. Cautions should be taken during injection of frontal sites as droopy 
eyelids, dry eyes and vision problem may result.
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7.2.3. Trigeminal neuralgia
Trigeminal neuralgia (TN) is known as sudden, usually unilateral severe recurrent stabbing 
pain involving the distribution of one or more branches of the trigeminal nerve [43]. It is caused 
by compression of the nerve near its origin. The pain is usually triggered by stimuli such as 
chewing, washing of the face, speech and tooth brushing [33]. It occurs more in the old patient 
rather than younger ones. Its management based on the prophylactic pharmacological treat-
ment with anti-epileptics including Carbamazepine, Oxcarbazepine, Bacloten, Lamotrigine, 
Gabapentin and ropivacaine. In case of unsatisfactory response or undesirable adverse effects, 
neurosurgical treatments are recommended which include peripheral techniques (cryosur-
gery, neurectomy, laser, acupuncture, thermocoagulation, injections of streptomycin, alcohol 
and phenol), Gasserian ganglion radiofrequency thermocoagulation, glycerol, balloon com-
pression, Gamma knife and microvascular decompression. All of these surgical treatments 
may cause damage to the nerve except microvascular decompression, which limits the con-
sideration of these techniques [44]. However, BT has been found to be minimally invasive and 
effective treatment of pain in the maxillofacial region over other invasive therapies especially, 
in cases of trigeminal neuralgia presenting no adverse effects [45, 46].
Injection technique: for the injection to the maxillary root, a dental needle of 0.40 × 50  mm 
is used through the upper edge of the zygomatic arch, midway between the external ear and 
the orbital rim, the needle should be pointed toward the zygomatic bone on the other side 
of the skull (forming obtuse angles to the front and below) at a depth of 50 mm around the 
pterygopalatine ganglion. For the injection to the mandibular root, through the lower edge 
Figure 4. Botox injection points for temporalis and masseter muscles in treatment of TMJ disorders.
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of the zygomatic arch, the position should be the same. The needle should be pointed trans-
versely along the base of the skull toward the middle, then to be inserted below the middle 
of the zygomatic arch. After striking the pterygoid process, the needle should be withdrawn 
slightly craniodorsally about 5–10 mm where the solution is administered around the trigemi-
nal ganglion [47].
7.2.4. Facial nerve palsy
It is a facial paralysis with resultant paresis and synkinesis of muscles on the affected side of 
the face, causing loss of forehead creases, loss of the nasolabial fold, lagophthalmos, brow 
droop, and drooping of the corner of the mouth. In contrast, muscles on the unaffected side of 
the face have no opposing forces [48]. Thus, lead to articulation difficulty, eating and drink-
ing problems, asymmetry of the face and unacceptable facial esthetics causing psychological 
and physical disturbance in a patient’s life. Treatments of facial palsy involve nerve grafts, 
muscle transfers, myofunctional approaches, and microsurgical patches. Although there are 
many treatment modalities, facial symmetry may persist. However, BT injection treatment 
was reported to be effective in reducing facial synkinesis, thus improving facial expression 
symmetry both at rest and involuntary movements [49]. One of the complications of facial 
nerve palsy is hyperlacrimation (crocodile tears) associated with salivation due to the abnor-
mal connection between secretomotor fibers of salivary gland to lacrimal gland. Injection of 
BT into the lacrimal gland has been successfully reported in managing this condition too [50].
Injection technique: the areas of injection that are usually considered are levator labii alae-
que nasi to reduce the visibility of the upper teeth; depressor labii inferioris to reduce the 
Figure 5. Injection sites of Botox into Frontalis, Corrugator and procerus muscles.
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visibility of the lower teeth and orbicularis oculi and frontalis to match the contralateral rhyt-
ides (Figure 1). Patient should be seated in an upright position with the head supported and 
asked to smile widely, Then, sites of injection are examined clinically, the area exhibiting the 
maximum pull on movement of the lower face are marked and is injected at an angle of 45° 
intramuscularly. The unaffected side is also injected to make balance, improve hyperkinesis 
and give more symmetry at rest. Titration is needed to reduce the effect of the intentional 
muscle function while increasing the treatment of unintended motion [51].
7.2.5. Bruxism and parafunctional habits
Parafunctional habits such as bruxism, clenching or grinding interfere with the normal occlu-
sion causing generalized attrition, masticatory muscle disharmony, TMJ disorder, facial pain 
and headache. Traditionally, oral appliances such as oral splint and night guard are indicated 
for such cases and give good success results as to relieving some or all of the symptoms. Also, 
BT has been introduced successfully to reduce these symptoms. However, in comparison of 
BT injections to oral splint modality, both of them are equally effective and safe on bruxism 
[52, 53] but use of BT in sleep bruxism is more encouraging and comfortable, also a single 
injection has been shown to be effective for at least a month [54].
Injection technique: injection sites identified by palpation during clenching, then receive 
bilateral injections of Botox in three sites in the thickest parts of the masseter muscles [55] with 
dose range of 25–100 U per side. Exceeding the dose will paralyze the muscles of mastication 
and interfere with the patient’s ability in chewing and talking. Also, too small doses will have 
no effect at all [56].
7.2.6. Salivary gland secretory disorders (excessive salivation/drooling)
The salivary gland secretory disorders cause excessive salivation, such as sialorrhea and Frey 
syndrome, they are due to poor oral and facial muscle control. They are common in patients 
with cerebral palsy or neurologic disorders, also patients have post-traumatic sialoceles and 
cysts, which commonly developed during cancer resection surgery. These disorders may 
cause perioral dermatitis, or dehydration which leads to problems in the hygiene and the 
psychosocial status [57]. Their treatment methods vary from a conservative medical modal-
ity to a more aggressive surgical approach, including oral motor therapy, intraoral devices, 
anticholinergic medications, and surgery. However, anticholinergic medications are poorly 
tolerated due to their adverse effects on the body, such as constipation, urinary retention, 
orthostatic hypotension, bradycardia, irritability and drowsiness. In addition, surgery is con-
sidered to be an invasive procedure that has complications, including increased dental caries, 
gingival problems, parotitis, and postoperative cysts and fistulae [58].
The secretion of saliva is under parasympathetic autonomic control with acetylcholine work-
ing as the specific neurotransmitter. Therefore, down regulation of acetylcholine by BT injec-
tions will lead to the decrease of the salivary production [59]. Lately, BT injections have been 
utilized to manage sialorrhea in adults with Parkinson’s disease, head and neck cancer, neu-
rodegenerative disorders and strokes without any noticeable side effects [57].
Injection technique: the injection of Botox into the parotid and submandibular glands is effec-
tive in controlling drooling [60, 61]. Botox is administered in a dose range of 30–70 U into parotid 
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gland. However, the significant reduction in salivary flow is usually observed at 4 weeks and 
fades in about 3 months, so repeated injections are necessary for such cases [61, 62].
7.2.7. Maxillofacial trauma and fractures
To avoid inappropriate muscle movements during healing period of fractured bones, BT have 
been introduced to be effective in this mission when there is a injury or fracture in the maxil-
lofacial region such as the maxilla, mandible, nasal bone, zygoma and orbital bone. Also, BT 
injections are used as a temporary splint during fracture healing period. BT injections into the 
masticatory muscles in cases of jaw fractures, have been reported to prevent bone displace-
ment and facilitate healing [63]. In 2003, Kayikçioglu et al. conducted a study in temporary 
paralysis of masseter muscles, to allow application of mini plates/microplates in the manage-
ment of zygomatic fractures [64]. Also, some reports recommended the use of BT injections in 
masseter and anterior fibers of temporalis muscles as an adjunctive modality in treatment of 
condylar fracture [63, 65]. In addition, BT injections in the anterior belly digastric have been 
used successfully in the correction of post-traumatic anterior open bite [66].
7.2.8. Adjunctive to dental treatments
7.2.8.1. Implantology
BT injections have been postulated to increase the therapeutic benefits in patients with implants 
who have excessive functional force or have parafunctional habits. When Botox relaxes the 
masticatory muscles, especially the masseter and temporalis muscles, it weakens the muscles 
movement in immediate or delayed implant loading. Hereby, relief the abnormal forces on 
implants leading to successful osseointegration and good prognosis of the treatment. However, 
studies supporting the use of BT in implantology is rare and warrants further research [7, 67].
7.2.8.2. Orthodontic therapy
The relapse of orthodontic treatment is a common problem because not only teeth are respon-
sible for the treatment relapse, but also the hyperactivity of facial muscles acts as a risk factor. 
Hereby, the BT injection of mentalis muscle and other muscles will decrease their strength 
and contractions which in turn avoid their disrupting to teeth alignment.
7.2.8.3. Removable prosthodontics
Some patients may suffer from difficulty in retention of their removable dentures due to 
hyperactivity or hypertrophy of their masticatory muscles such as masseter, lateral and 
medial pterygoid muscles. Therefore, weakening the contractions of these muscles by BT 
injections, increases the retention of the removable dentures.
7.2.8.4. Periodontal and dental health
As it is well known that there is a relation between stress and periodontal diseases as it decreases 
the immunity affecting the host inflammatory response to local factors, in turn increasing 
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the inflammation and periodontal destruction. However, a recent study has reported that BT 
injections improve the psychological status and release stress as Botox injections improve the 
facial appearance, causing increase in the immunity and health of periodontium [4]. In addi-
tion, decreasing stress and relief of grinding and bruxism habits will prevent the traumatized 
occlusion leading to the improvement of the dental and periodontal health.
7.2.8.5. Mandibular trismus
After a prolonged time of dental procedures, patient may complain of pain and limitation 
of mouth opening due to spasm of masticatory muscles. Thus, may affect the compliance of 
dental treatment, restrict the oral hygiene regime, difficulty in drinking and eating. Botox 
injections into masticatory muscles will reduce pain, paralysis the muscles and diminish the 
spastic activity.
7.2.8.6. Diagnostic application for toothache
In cases of chronic intermittent toothache, BT injections can be used to identify the origin of 
the pain and distinguish if the pain is due to muscles or teeth. The pain of pulpal origin will 
not be relieved when Botox is injected into the muscles [9].
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